 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
1h0i
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
Complex of a chitinase with the natural product cyclopentape argifin from gliocladium
|
|
Structure:
|
 |
Chitinase b. Chain: a, b. Engineered: yes. Argifin. Chain: c, d. Engineered: yes
|
|
Source:
|
 |
Serratia marcescens. Organism_taxid: 615. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Gliocladium. Organism_taxid: 62887
|
|
Biol. unit:
|
 |
Dimer (from PDB file)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.192
|
R-free:
|
0.232
|
|
|
Authors:
|
 |
D.R.Houston,K.Shiomi,N.Arai,S.Omura,M.G.Peter,A.Turberg,B.Sy V.G.H.Eijsink,D.M.F.Aalten
|
Key ref:
|
 |
D.R.Houston
et al.
(2002).
High-resolution structures of a chitinase complexed with natural product cyclopentapeptide inhibitors: mimicry of carbohydrate substrate.
Proc Natl Acad Sci U S A,
99,
9127-9132.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
19-Jun-02
|
Release date:
|
27-Jun-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P11797
(CHIB_SERMA) -
Chitinase B
|
|
|
|
Seq: Struc:
|
 |
 |
 |
499 a.a.
497 a.a.*
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 7 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.2.1.14
- Chitinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of the 1,4-beta-linkages of N-acetyl-D-glucosamine polymers of chitin.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
1 term
|
 |
|
Biological process
|
carbohydrate metabolic process
|
2 terms
|
 |
|
Biochemical function
|
catalytic activity
|
5 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
99:9127-9132
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
High-resolution structures of a chitinase complexed with natural product cyclopentapeptide inhibitors: mimicry of carbohydrate substrate.
|
|
D.R.Houston,
K.Shiomi,
N.Arai,
S.Omura,
M.G.Peter,
A.Turberg,
B.Synstad,
V.G.Eijsink,
D.M.van Aalten.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Over the past years, family 18 chitinases have been validated as potential
targets for the design of drugs against human pathogens that contain or interact
with chitin during their normal life cycles. Thus far, only one potent chitinase
inhibitor has been described in detail, the pseudotrisaccharide allosamidin.
Recently, however, two potent natural-product cyclopentapeptide chitinase
inhibitors, argifin and argadin, were reported. Here, we describe
high-resolution crystal structures that reveal the details of the interactions
of these cyclopeptides with a family 18 chitinase. The structures are examples
of complexes of a carbohydrate-processing enzyme with high-affinity
peptide-based inhibitors and show in detail how the peptide backbone and side
chains mimic the interactions of the enzyme with chitooligosaccharides. Together
with enzymological characterization, the structures explain why argadin shows an
order of magnitude stronger inhibition than allosamidin, whereas argifin shows
weaker inhibition. The peptides bind to the chitinase in remarkably different
ways, which may explain the differences in inhibition constants. The two
complexes provide a basis for structure-based design of potent chitinase
inhibitors, accessible by standard peptide chemistry.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Fig. 2. Argifin and argadin complexed to ChiB. The
previously published structure of mutationally inactivated ChiB
(where the catalytic Glu-144 has been replaced with a glutamine)
in complex with GlcNAc[5] (NAG[5]; ref. 17) is shown as a stereo
stick model and compared with the ChiB-argifin and ChiB-argadin
complexes. Unbiased (i.e., before including any inhibitor model)
|F[o] F[c]|,
[calc]
(contoured at 2.5 ) maps are
shown in orange. Ligand carbon atoms are colored purple. Side
chains interacting with the cyclopentapeptides are shown in a
sticks representation with carbons colored gray except for the
catalytic residue 144, for which carbons are shown in yellow.
Tyr-145 (which only hydrogen-bonds to GlcNAc[5]; see also Fig.
3) has been omitted to improve clarity. Water molecules
hydrogen-bonding to both protein and inhibitor are shown as
green spheres (hydrogen bonds are not shown). Hydrogen bonds
between the ligands and the protein side chains are shown as
black dotted lines. Argifin/argadin intramolecular hydrogens
bonds are shown as green dotted lines. In the complex with
GlcNAc[5], the sugar subsites are indicated by green labels.
|
 |
Figure 3.
Fig. 3. Further details of inhibitor-ChiB interactions.
Schematic protein-ligand interactions (Left, calculated with
LIGPLOT; ref. 37) and surface plots are shown for three ChiB
complexes. The ChiB-GlcNAc[5] (NAG[5]) complex (17) is shown,
for comparison purposes, together with the ChiB-argifin and
ChiB-argadin complexes described here. In the schematic
drawings, only protein-ligand hydrogen bonds are shown (see
key). For the complex with GlcNAc[5], only the central three
sugars are shown. In the surface representations, the protein
surface is colored gray with the exception of Trp-97 and Trp-220
(blue) and the catalytic acid Glu-144 (red). The ligands are
shown in a sticks representation with carbons colored green. The
sugar subsites are labeled in the GlcNAc[5] complex.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.W.Schüttelkopf,
L.Gros,
D.E.Blair,
J.A.Frearson,
D.M.van Aalten,
and
I.H.Gilbert
(2010).
Acetazolamide-based fungal chitinase inhibitors.
|
| |
Bioorg Med Chem, 18,
8334-8340.
|
 |
|
|
|
|
 |
C.L.Rush,
A.W.Schüttelkopf,
R.Hurtado-Guerrero,
D.E.Blair,
A.F.Ibrahim,
S.Desvergnes,
I.M.Eggleston,
and
D.M.van Aalten
(2010).
Natural product-guided discovery of a fungal chitinase inhibitor.
|
| |
Chem Biol, 17,
1275-1281.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.J.La Clair
(2010).
Natural product mode of action (MOA) studies: a link between natural and synthetic worlds.
|
| |
Nat Prod Rep, 27,
969-995.
|
 |
|
|
|
|
 |
T.Hirose,
T.Sunazuka,
and
S.Omura
(2010).
Recent development of two chitinase inhibitors, Argifin and Argadin, produced by soil microorganisms.
|
| |
Proc Jpn Acad Ser B Phys Biol Sci, 86,
85.
|
 |
|
|
|
|
 |
T.M.Gloster,
and
G.J.Davies
(2010).
Glycosidase inhibition: assessing mimicry of the transition state.
|
| |
Org Biomol Chem, 8,
305-320.
|
 |
|
|
|
|
 |
A.M.Olland,
J.Strand,
E.Presman,
R.Czerwinski,
D.Joseph-McCarthy,
R.Krykbaev,
G.Schlingmann,
R.Chopra,
L.Lin,
M.Fleming,
R.Kriz,
M.Stahl,
W.Somers,
L.Fitz,
and
L.Mosyak
(2009).
Triad of polar residues implicated in pH specificity of acidic mammalian chitinase.
|
| |
Protein Sci, 18,
569-578.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Hirose,
T.Sunazuka,
A.Sugawara,
A.Endo,
K.Iguchi,
T.Yamamoto,
H.Ui,
K.Shiomi,
T.Watanabe,
K.B.Sharpless,
and
S.Omura
(2009).
Chitinase inhibitors: extraction of the active framework from natural argifin and use of in situ click chemistry.
|
| |
J Antibiot (Tokyo), 62,
277-282.
|
 |
|
|
|
|
 |
V.Kairys,
M.K.Gilson,
V.Lather,
C.A.Schiffer,
and
M.X.Fernandes
(2009).
Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis.
|
| |
Chem Biol Drug Des, 74,
234-245.
|
 |
|
|
|
|
 |
C.Petter,
C.Scholz,
H.Wessner,
G.Hansen,
P.Henklein,
T.Watanabe,
and
W.Höhne
(2008).
Phage display screening for peptidic chitinase inhibitors.
|
| |
J Mol Recognit, 21,
401-409.
|
 |
|
|
|
|
 |
H.Prinz
(2008).
How to identify a pharmacophore.
|
| |
Chem Biol, 15,
207-208.
|
 |
|
|
|
|
 |
O.A.Andersen,
A.Nathubhai,
M.J.Dixon,
I.M.Eggleston,
and
D.M.van Aalten
(2008).
Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin.
|
| |
Chem Biol, 15,
295-301.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Zaheer-ul-Haq,
P.Dalal,
N.N.Aronson,
and
J.D.Madura
(2007).
Family 18 chitolectins: comparison of MGP40 and HUMGP39.
|
| |
Biochem Biophys Res Commun, 359,
221-226.
|
 |
|
|
|
|
 |
F.H.Cederkvist,
A.D.Zamfir,
S.Bahrke,
V.G.Eijsink,
M.Sørlie,
J.Peter-Katalinić,
and
M.G.Peter
(2006).
Identification of a high-affinity-binding oligosaccharide by (+) nanoelectrospray quadrupole time-of-flight tandem mass spectrometry of a noncovalent enzyme-ligand complex.
|
| |
Angew Chem Int Ed Engl, 45,
2429-2434.
|
 |
|
|
|
|
 |
F.V.Rao,
O.A.Andersen,
K.A.Vora,
J.A.Demartino,
and
D.M.van Aalten
(2005).
Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.
|
| |
Chem Biol, 12,
973-980.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Dolecková-Maresová,
M.Pavlík,
M.Horn,
and
M.Mares
(2005).
De novo design of alpha-amylase inhibitor: a small linear mimetic of macromolecular proteinaceous ligands.
|
| |
Chem Biol, 12,
1349-1357.
|
 |
|
|
|
|
 |
O.A.Andersen,
M.J.Dixon,
I.M.Eggleston,
and
D.M.van Aalten
(2005).
Natural product family 18 chitinase inhibitors.
|
| |
Nat Prod Rep, 22,
563-579.
|
 |
|
|
|
|
 |
B.Synstad,
S.Gåseidnes,
D.M.Van Aalten,
G.Vriend,
J.E.Nielsen,
and
V.G.Eijsink
(2004).
Mutational and computational analysis of the role of conserved residues in the active site of a family 18 chitinase.
|
| |
Eur J Biochem, 271,
253-262.
|
 |
|
|
|
|
 |
H.Hu,
G.Wang,
H.Yang,
J.Zhou,
L.Mo,
K.Yang,
C.Jin,
C.Jin,
and
Z.Rao
(2004).
Crystallization and preliminary crystallographic analysis of a native chitinase from the fungal pathogen Aspergillus fumigatus YJ-407.
|
| |
Acta Crystallogr D Biol Crystallogr, 60,
939-940.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|